D. Western Therapeutics Institute Inc (4576):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:D. Western Therapeutics Institute Inc (4576) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8019
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
D. Western Therapeutics Institute Inc (DWTI) is a pharmaceutical product s developer. The company offers ophthalmic solution, WP-1303, H-1337, K-134 and DW-1002. It discovers and develops drugs for glaucoma. DWTI’s ophthalmic solution treats glaucoma and ocular hypertension treatment and arteriosclerosis obliterans. The company’s glanatek is an opthalmic solution with composition of ripasudil hydrochloride hydrate developed for the treatment of glaucoma through its intraocular pressure lowering action. It offers licensing out and promotion of development. The company operates in Japan, The US, Korea and Europe. DWTI is headquartered in Nagoya, Japan.

D. Western Therapeutics Institute Inc (4576) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
D. Western Therapeutics Institute Inc, Medical Devices Deals, 2012 to YTD 2018 9
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
D.Western Therapeutics Institute Acquires Ophthalmic Surgical Adjuvant Business from Healios for USD11 Million 12
Partnerships 13
D. Western Therapeutics Institute Enters into Option Agreement with Allysta Pharma 13
Glaukos Enters into Development Agreement with D. Western Therapeutics Institute 14
Edit Force Enters into Research Agreement with Japan Innovative Therapeutics 15
D.Western Therapeutics Institute Enters into Research Agreement with Chiba University 16
D.Western Therapeutics Institute Enters into Research Agreement with University of Toyama 17
D. Western Therapeutics Institute Enters into Strategic Agreement with Allysta Pharma 18
Licensing Agreements 19
Japan Innovative Therapeutics Enters into Licensing Agreement with Institute of Neuroimmunology 19
D.Western Therapeutics Institute Plans to Enter into Option Agreement for H-1129 20
Wakamoto Pharma Enters into Licensing Agreement with D. Western Therapeutics Institute 21
D.Western Therapeutics Institute Enters into Licensing Agreement with Doshisha University 22
Equity Offering 23
D.Western Therapeutics Institute Raises USD2 Million in Private Placement of Shares, upon Exercise of Warrants 23
D. Western Therapeutics Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 24
D. Western Therapeutics Raises USD2.3 Million in Private Placement of Shares upon Exercise of Warrants 25
D. Western Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 26
Acquisition 27
ROHTO Pharma Acquires 59.43% Stake in Japan Innovative Therapeutics for USD44 Million 27
D. Western Therapeutics Institute Inc – Key Competitors 28
D. Western Therapeutics Institute Inc – Key Employees 29
D. Western Therapeutics Institute Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
D. Western Therapeutics Institute Inc, Deals By Therapy Area, 2012 to YTD 2018 8
D. Western Therapeutics Institute Inc, Medical Devices Deals, 2012 to YTD 2018 9
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
D.Western Therapeutics Institute Acquires Ophthalmic Surgical Adjuvant Business from Healios for USD11 Million 12
D. Western Therapeutics Institute Enters into Option Agreement with Allysta Pharma 13
Glaukos Enters into Development Agreement with D. Western Therapeutics Institute 14
Edit Force Enters into Research Agreement with Japan Innovative Therapeutics 15
D.Western Therapeutics Institute Enters into Research Agreement with Chiba University 16
D.Western Therapeutics Institute Enters into Research Agreement with University of Toyama 17
D. Western Therapeutics Institute Enters into Strategic Agreement with Allysta Pharma 18
Japan Innovative Therapeutics Enters into Licensing Agreement with Institute of Neuroimmunology 19
D.Western Therapeutics Institute Plans to Enter into Option Agreement for H-1129 20
Wakamoto Pharma Enters into Licensing Agreement with D. Western Therapeutics Institute 21
D.Western Therapeutics Institute Enters into Licensing Agreement with Doshisha University 22
D.Western Therapeutics Institute Raises USD2 Million in Private Placement of Shares, upon Exercise of Warrants 23
D. Western Therapeutics Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 24
D. Western Therapeutics Raises USD2.3 Million in Private Placement of Shares upon Exercise of Warrants 25
D. Western Therapeutics Raises Funds through Private Placement of Shares upon Exercise of Warrants 26
ROHTO Pharma Acquires 59.43% Stake in Japan Innovative Therapeutics for USD44 Million 27
D. Western Therapeutics Institute Inc, Key Competitors 28
D. Western Therapeutics Institute Inc, Key Employees 29
D. Western Therapeutics Institute Inc, Subsidiaries 30

List of Figures
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
D. Western Therapeutics Institute Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
D. Western Therapeutics Institute Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[D. Western Therapeutics Institute Inc (4576):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • San Gold Corporation:企業の戦略・SWOT・財務分析
    SummarySan Gold Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Fi …
  • Ambry Genetics Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • Alfresa Holdings Corp (2784):企業財務及び戦略的SWOT分析
    Summary Alfresa Holdings Corp (Alfresa) is a pharmaceutical company that manufactures and markets diagnostic reagent and medical devices. The company’s business includes ethical pharmaceuticals wholesaling, self-medication products and manufacturing. It’s ethical pharmaceutical wholesaling business …
  • Molecular Targeting Technologies, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Molecular Targeting Technologie …
  • Tokheim Group S.A.S.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Tokheim Group S.A.S. Mergers an …
  • Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group develops and markets pharmaceutical products in the field of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor …
  • Litgrid AB (LGD1L):企業の財務・戦略的SWOT分析
    Litgrid AB (LGD1L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sberbank of Russia:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sberbank of Russia Mergers and …
  • The Carlyle Group LP (CG):企業の財務・戦略的SWOT分析
    The Carlyle Group LP (CG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • JSC Trasta Komercbanka:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' JSC Trasta Komercbanka Mergers …
  • Victorian WorkCover Authority:企業の戦略的SWOT分析
    Victorian WorkCover Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Logi Analytics (formerly LogiXML, Inc.):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Logi Analytics (formerly LogiXM …
  • Suryachakra Power Corporation Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Suryachakra Power Corporation L …
  • Denbury Resources Inc.:企業の戦略・SWOT・財務情報
    Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • CMS Energy Corporation (CMS):企業のM&A・提携動向(発電分野)
    Summary CMS Energy Corporation (CMS Energy) is an energy utility company that provides utility services related to natural gas and electricity. It offers gas and electricity services through its subsidiaries, namely, Consumers Energy (Consumers) and CMS Enterprises. Consumers is an electric and gas …
  • Checkers Drive-In Restaurants, Inc.:企業の戦略・SWOT・財務分析
    SummaryCheckers Drive-In Restaurants, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the …
  • Precision System Science Co Ltd (7707)-医療機器分野:企業M&A・提携分析
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company’s products include automated nucleic acid isolation system, large sample volume nucleic acid extraction sy …
  • The Valspar Corporation (VAL):企業の財務及び戦略的SWOT分析
    The Valspar Corporation (VAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • PT. Agis Tbk:企業の戦略・SWOT・財務分析
    SummaryPT. Agis Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - …
  • Mapi Pharma Ltd (MAPI):企業のM&A・提携動向(医療分野)
    Summary Mapi Pharma Ltd (Mapi) is a development stage pharmaceutical company that carries out the development of generic drugs including life cycle management (LCM) products, active pharmaceutical ingredients (APIs) and formulations. It develops two LCM products for the treatment of multiple scleros …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆